Syros Pharmaceuticals, Inc. - common stock (SYRS) News
Filter SYRS News Items
SYRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SYRS News Highlights
- SYRS's 30 day story count now stands at 2.
- Over the past 13 days, the trend for SYRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest SYRS News From Around the Web
Below are the latest news stories about Syros Pharmaceuticals Inc that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical CompanyCAMBRIDGE, Mass., January 10, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical development programs and outlined its strategic priorities and upcoming expected milestones. |
Here's Why Syros Pharmaceuticals (NASDAQ:SYRS) Can Manage Its Debt Despite Losing MoneySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... |
-$0.44 Earnings Per Share Expected for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) This QuarterEquities analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will announce earnings per share (EPS) of ($0.44) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Syros Pharmaceuticals earnings, with estimates ranging from ($0.48) to ($0.38). Syros Pharmaceuticals reported earnings of ($0.61) per share in the same quarter last year, [] |
-$0.44 EPS Expected for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) This QuarterAnalysts forecast that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.48). Syros Pharmaceuticals posted earnings per share of [] |
Syros Pharmaceuticals Inc. (SYRS): Significant Improvements, Worth Being ConsideredSyros Pharmaceuticals Inc. (NASDAQ:SYRS) concluded the trading at $3.55 on Friday, December 03 with a fall of -7.07% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.82 and 5Y monthly beta was reading 1.88. Considering stocks 52-week price range provides that Syros Pharmaceuticals Inc. (SYRS): Significant Improvements, Worth Being Considered Read More » |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
Nuveen Asset Management LLC Raises Stock Position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)Nuveen Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,514 shares of the companys stock after purchasing an additional 33,901 shares during the [] |
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expected to Post Quarterly Sales of $5.65 MillionBrokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to post $5.65 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Syros Pharmaceuticals earnings. The highest sales estimate is $6.00 million and the lowest is $5.00 million. Syros Pharmaceuticals posted sales of $5.70 million in the same quarter last year, which [] |
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Shares Bought by Northern Trust CorpNorthern Trust Corp raised its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 6.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 554,422 shares of the companys stock after purchasing an additional 34,517 shares during the quarter. Northern Trust Corp owned [] |
Syros to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings. Piper Sandler 33rd Annual Healthcare Conference Date: Tuesday, November 23, 2021 Presentation Time: A pre-recorded fireside chat will be |